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The parental hu14.18-IL-2 immunocytokine (ICp) is a
fusion protein where one human IL-2 molecule is attached
to each of the heavy chains of the intact humanized form
of the anti-GD2 monoclonal antibody (mAb). Early clinical
trials have shown that ICp treatment can lead to complete
responses; however, dosing is limited by IL-2-induced
toxicity. Evidence suggests that the anti-tumor efficacy of
IL-2 is achieved through activation of immune cells
expressing high-affinity IL-2 receptors (abg IL-2Rs) while
IL-2 induced toxicity is related to over-stimulation
of immune cells expressing intermediate affinity IL-2
receptors (bg IL-2Rs). We have shown that ICp stimulates
murine bg IL-2R to a lesser degree than the human form,
but is still able to induce potent anti-tumor effects in vivo.
We believe this difference in the ICp selectivity profile for
murine IL-2Rs may account for the successful retention of
the anti-tumor effect and reduced IL-2 toxicity observed
in mice. To study the effect of IL-2R selectivity on efficacy
and toxicity we have created IC35 and ICSK, a novel
generation of anti-GD2 ICs with varying levels of affinity
for bg IL-2Rs. These two new constructs, IC35 and ICSK,
have the IL-2 molecules fused to the C-terminus of the
light chains of the hu14.18 mAb rather than to the heavy
chains. This modification limits access to a critical contact
residue of IL-2 by the b-chain thereby hindering the ability
of IC35 to bind to bg IL-2Rs. In contrast to IC35, ICSK
contains a mutated IL-2 protein with increased affinity for
bg IL-2Rs. Here, we evaluated the ability of IC35 and ICSK
to bind and induce proliferation of mouse and human cells
expressing abg or bgIL-2Rs. We found that IC35 and
ICSK maintained binding and activation of both human
and mouse abg IL-2Rs. In contrast, IC35 had a ~50-fold
reduction or complete loss of its ability to stimulate
proliferation of human and mouse cells expressing bg
IL-2Rs, respectively. Notably, ICSK had an increased abil-
ity to stimulate mouse cells expressing bg IL-2Rs resulting
in similar receptor activity and selectivity that IC35 has for
human immune cells. Overall, our data indicate that ICSK
can be used in mouse models to study the effects of over
stimulation of bg IL-2Rs and its relation to IL-2 induced
toxicity. In addition, IC35’s reduced ability to stimulate
human bg IL-2Rs suggests it may be a candidate for retain-
ing anti-tumor activity with less dose-limiting IL-2 toxicity
in clinical trials.
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